NCT03007537

The Prevention of Erythropoietin on Cardiac Surgery-associated Acute Kidney Injury

• Status: Terminated
• Phase: N/A
• Study type: Interventional
• Enrollment: 101 (actual)
• Sponsor: Nanjing First Hospital, Nanjing Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To testify the prevention of Erythropoietin on cardiac surgery associated-acute kidney injury, and trying to provide evidence for protecting the renal function and improving the prognosis for patients after cardiac surgery.

Detailed description

Patients meet the inclusion criteria and agree to sign an informed consent will be randomly assigned into the control group or erythropoietin group.Interventions will be applied 1 day(24hrs) before the cardiac surgery. Blood and Urine samples will be collected after the surgery. By using the criterion given by KDIGO2012 and testing the biomarkers for acute kidney injury, we hope to find out if there is an association between erythropoietin administration and the occurence of acute kidney injury.

Conditions

• Acute Kidney Injury
• Cardiac Disease
• Surgery

Interventions

Type	Name	Description
DRUG	Erythropoietin	10000 IU erythropoietin, subcutaneous injection
DRUG	0.9% sodium chloride	0.9% sodium chloride 1ml, subcutaneous injection
PROCEDURE	cardiac surgery	included valve, coronary artery bypass graft or surgery for congenital heart diseases

Timeline

• Start date: 2015-10-01
• Primary completion: 2018-12-28
• Completion: 2018-12-28
• First posted: 2017-01-02
• Last updated: 2023-01-26
• Results posted: 2023-01-26

Locations

1 site across 1 country: China